Flex Pharma, which is developing dietary supplements for the treatment of muscle cramps and spasms, raised $86 million by offering 5.4 million shares at $16, above the range of $12 to $14. The company originally planned to offer 4.6 million shares. Flex Pharma plans to list on the NASDAQ under the symbol FLKS. Flex Pharma initially filed confidentially on 10/29/2014. Jefferies & Co. and Piper Jaffray acted as lead managers on the deal.
